Jianping Li, MD
Assistant Professor, Department of Pharmacology, Physiology, & Cancer Biology
Contact
Bluemle Life Sciences Building
233 S. 10th Street
802 BLSB
Philadelphia, PA 19107
Featured Links
Jianping Li, MD
Assistant Professor, Department of Pharmacology, Physiology, & Cancer Biology
Expertise & Research Interests
I am a physician-scientist with expertise in hematology and oncology, I have more than ten years of experience as a hematologist. I had excellent postdoctoral training and gained extensive experience and knowledge of cutting-edge translational research about epigenetic regulation in blood cancers. My research interests cover epigenetics, multiple-genomics, blood cancer biology, hematopoietic stem cells/cancer stem cells, T-cell immunity, and translational target therapeutics. I have studied how mutations of chromatin regulators impact hematopoiesis, leukemia relapse, and therapy resistance using conditional mouse models, patient-derived xenograft (PDX), and multi-omics technologies. Findings from my work include 1) demonstration of the critical role of ASXL2 in myeloid malignancies; 2) elucidation of the aberrant epigenetic landscape underlying the mechanism of relapse of acute lymphoblastic leukemia and mantle cell lymphoma driven by NSD2 mutation; and 3) utilizing the insight of epigenetic mechanisms and developing novel targeting therapies to overcome glucocorticoid resistance driven by NSD2 mutation. My long-term research goal is to understand the role of chromatin regulators in normal and malignant hematopoiesis, demonstrate the molecular mechanisms underlying the initiation and relapse of blood cancers, and ultimately develop novel and effective therapies to help patients suffering from blood cancers.
Publications
- KDM6A regulates immune response genes in multiple myeloma
- Recruitment of FBXO22 for targeted degradation of NSD2
- HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers
- DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
- PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia